Houston hospitals got their report cards. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Close to half of the Houston area's general acute-care hospitals are at the top of their class, according to new safety grades assigned to U.S. hospitals. But one hospital in the region is failing on the safety front, the grades show.

In its fall 2019 report card for acute-care hospitals, The Leapfrog Group gives letter grades of A, B, C, D, and F based on the hospitals' ability to shield patients from avoidable errors, injuries, accidents, and infections. The nonprofit represents hundreds of public and private employers that buy healthcare benefits.

In the Houston area, 19 hospitals earned an A, with 14 receiving a B, seven getting a C, one picking up a D and one being slapped with an F.

Chris Skisak, executive director of the Houston Business Coalition on Health, notes that 23 percent of hospitals in the Houston areas saw their Leapfrog grades go up while just 11 percent saw their grades go down. The coalition is a regional leader for The Leapfrog Group.

"Houston-area hospitals do care about their grades," Skisak says, "and going back to 2016, most obtained a higher grade after receiving a lower grade the previous assessment period. Houston is fortunate to have [about] 50 percent of its hospitals earn consistent A grades."

For the first time in at least four years, The Leapfrog Group did hit one Houston-area hospital — Huntsville Memorial Hospital — with an F. On the spring 2019 report card, the hospital received a D. In the fall of 2018, the mark was a C.

Huntsville Memorial Hospital currently is combating what's been described as a "dire financial situation."

In a November 1 statement, the Walker County Hospital District, which owns the Huntsville hospital, said the separate nonprofit entity that runs the hospital — Walker County Hospital Corp. — was beset by monetary woes and was on the verge of declaring Chapter 11 bankruptcy. As a result, the district warned, the hospital might close.

According to The Huntsville Item, a proposed rescue of the hospital would place ownership and management in the hands of a joint venture between the hospital district and Plano-based Community Hospital Corp., a hospital management company. The nonprofit Plano company provides supply-chain services to a Huntsville medical practice, Huntsville Orthopedic Surgery and Sports Medicine PLLC.

In the statement, the district's board says it "remains committed to maintaining a viable hospital for the community and to improving hospital operations and services."

The Leapfrog Group graded a total of 42 hospitals in the Houston area. The nonprofit released its fall 2019 report card on November 7.

Houston-area hospitals that earned an A were:

  • Houston Methodist Baytown Hospital
  • HCA Houston Healthcare Conroe
  • HCA Houston Healthcare West
  • Houston Methodist Hospital
  • Houston Methodist West Hospital
  • Houston Methodist Willowbrook Hospital
  • Memorial Hermann Southeast
  • Memorial Hermann Southwest Hospital
  • Memorial Hermann Northeast, Humble
  • Memorial Hermann Katy Hospital
  • HCA Houston Healthcare Kingwood
  • CHI St. Luke's Health Memorial Livingston
  • Houston Methodist Clear Lake Hospital in Nassau Bay
  • HCA Houston Healthcare Pearland
  • Houston Methodist Sugar Land Hospital
  • CHI St. Luke's Health The Woodlands Hospital
  • Houston Methodist The Woodlands Hospital
  • Memorial Hermann The Woodlands Hospital
  • HCA Houston Healthcare Clear Lake in Webster

Skisak says the Leapfrog report card "is a valuable resource for employers to share with their employees so that they can self-navigate to the safest and highest quality hospitals."

"The Leapfrog Hospital Safety Grade offers critical patient safety information to consumers, in an easily digestible way, so that they can make informed decisions about where they seek care in the Houston area," he says in a release.

The Leapfrog Group bases its twice-a-year grades for hospital safety on 28 sets of publicly available data from more than 2,600 U.S. hospitals.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”